Sandoz sues to clear path for generic Prandin; Celgene board OKs $2B in buybacks;

@FiercePharma: Ranbaxy could waive Lipitor rights, let a rival generic to market...for a fee. If it can't get straight with FDA first. Article | Follow @FiercePharma

> Sandoz has asked a U.S. court to rule that its knock-off version of Novo Nordisk's diabetes drug Prandin will not infringe on the Danish company's patent. News

> Celgene's ($CELG) board authorized another $2 billion in stock buy-backs, adding to the $2.25 billion left from a previous program. Item

> Apricus Biosciences ($APRI) got the FDA nod for its Tolnaftate-D antifungal cream, its first product to be sold in the U.S. Story

> Swiss drugmaker Basilea Pharmaceutica posted a narrower net loss as a loss of contract revenue was partly offset by growing product sales. Article

> Merck's ($MRK) consumer products group is hunting for a global agency to handle its over-the-counter drug brands. Report

> Sagent Pharmaceuticals ($SGNT) launched its version of Norcuron, an injectable treatment for myasthenia gravis. News

> Valeant Pharmaceuticals ($VRX) said board member Michael Van Every has resigned for health reasons. Item

Biotech News

@FierceBiotech: Stanford investigators use "online dating" to match old drugs with new medical uses. Story | Follow @FierceBiotech

@JohnCFierce: Funny Icahn threat in conceding Forest bod vote. Imclone, Biogen, Genzyme all took time. (I'll be baa-a-a-ack.) More | Follow @JohnCFierce

@RyanMFierce: Hmm. Ireland-based academic says that private biotech spinoffs do better than those from universities Piece | Follow @RyanMFierce

@MaureenFierce: The other dark side of Merck's 13,000 layoffs: pharma's moving to greener pastures. Story | Follow @MaureenFierce

> GSK-owned Sirtris drug extends lives of obese mice. Story 

> Dendreon's fall trips up fellow biotechs on Wall Street. News 

> Roche targets 'good cholesterol' drug win where rivals failed. Story 

> Biotech venture to create 150 jobs in Florida. Article 

> Amgen drug shows it can 'improve heart function' in Ph2. News 

> China draws expats from U.S. to launch biotechs. Item

And Finally... One in 5 people seeking bankruptcy protection blames medical bills. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.